Latest news with #AureliaMetals
Yahoo
22-05-2025
- Business
- Yahoo
Aurelia Metals And 2 Other ASX Penny Stocks To Consider
The Australian market is facing a cautious start today, with the ASX 200 expected to open down by 0.89% amid concerns stemming from U.S. trade issues and recent volatility in global markets. In such uncertain times, investors might find opportunities in penny stocks—smaller or newer companies that can offer unique value propositions despite being an older term for investment areas. This article explores three penny stocks on the ASX that stand out for their financial resilience and potential growth, making them intriguing options for those looking to diversify beyond established names. Name Share Price Market Cap Financial Health Rating Lindsay Australia (ASX:LAU) A$0.69 A$218.85M ★★★★☆☆ CTI Logistics (ASX:CLX) A$1.80 A$144.98M ★★★★☆☆ Accent Group (ASX:AX1) A$1.905 A$1.15B ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$1.56 A$73.59M ★★★★★★ IVE Group (ASX:IGL) A$2.57 A$396.25M ★★★★★☆ GTN (ASX:GTN) A$0.605 A$115.6M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$3.57 A$169.4M ★★★★★★ Regal Partners (ASX:RPL) A$2.16 A$726.11M ★★★★★★ Navigator Global Investments (ASX:NGI) A$1.725 A$845.39M ★★★★★☆ Tasmea (ASX:TEA) A$2.90 A$673.74M ★★★★★☆ Click here to see the full list of 999 stocks from our ASX Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Aurelia Metals Limited is involved in the exploration and production of mineral properties in Australia, with a market cap of A$524.70 million. Operations: The company's revenue is primarily derived from its mining operations, with A$5.98 million from the Hera Mine, A$245.13 million from the Peak Mine, and A$73.90 million from the Dargues Mine. Market Cap: A$524.7M Aurelia Metals has shown a significant turnaround by becoming profitable recently, with net income of A$17.95 million for the half year ending December 2024, compared to a prior net loss. The company's operating cash flow covers its debt well, highlighting strong financial management. However, its Return on Equity remains low at 4.3%, and interest payments are not fully covered by EBIT. Despite these challenges, Aurelia's stock is trading significantly below estimated fair value and has not seen meaningful shareholder dilution recently. Recent presentations at industry events may also enhance investor visibility and confidence in future prospects. Unlock comprehensive insights into our analysis of Aurelia Metals stock in this financial health report. Gain insights into Aurelia Metals' outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Bravura Solutions Limited develops, licenses, and maintains software applications for the wealth management and funds administration sectors across Australia, the United Kingdom, New Zealand, and internationally, with a market cap of A$959.36 million. Operations: Bravura Solutions generates revenue from its software applications for wealth management and funds administration, with significant contributions from Australia, the United Kingdom, New Zealand, and other international markets. Market Cap: A$959.36M Bravura Solutions has recently become profitable, supported by a strong balance sheet with no debt and short-term assets exceeding liabilities. The company is trading at a favorable value compared to peers, with a Price-to-Earnings ratio of 13.4x versus the broader Australian market's 17.9x. Despite this, earnings are forecast to decline over the next three years by an average of 18.3% annually. The board's inexperience may pose challenges as it adapts to leadership changes following the appointment of an interim CEO in April 2025 after being dropped from the S&P/ASX Emerging Companies Index in March. Take a closer look at Bravura Solutions' potential here in our financial health report. Learn about Bravura Solutions' future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Dimerix Limited is an Australian biopharmaceutical company focused on developing and commercializing pharmaceutical products for unmet medical needs, with a market cap of A$339.37 million. Operations: Dimerix generates revenue primarily from its biotechnology segment, amounting to A$0.74 million. Market Cap: A$339.37M Dimerix is a pre-revenue biopharmaceutical company with a market cap of A$339.37 million, focusing on unmet medical needs. Despite its unprofitability and increased losses over the past five years, Dimerix's recent developments include an exclusive U.S. licensing agreement with Amicus Therapeutics for DMX-200, a Phase 3 drug candidate for FSGS kidney disease. The company's short-term assets cover both short and long-term liabilities, providing some financial stability despite less than one year of cash runway if free cash flow continues to decline at historical rates. The board and management are considered experienced, which may aid in navigating future challenges. Get an in-depth perspective on Dimerix's performance by reading our balance sheet health report here. Review our historical performance report to gain insights into Dimerix's track record. Click here to access our complete index of 999 ASX Penny Stocks. Curious About Other Options? Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:AMI ASX:BVS and ASX:DXB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Aurelia Metals (ASX:AMI) shareholders have earned a 70% return over the last year
If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right individual stocks, you could make more than that. For example, the Aurelia Metals Limited (ASX:AMI) share price is up 70% in the last 1 year, clearly besting the market return of around 4.4% (not including dividends). If it can keep that out-performance up over the long term, investors will do very well! Unfortunately the longer term returns are not so good, with the stock falling 11% in the last three years. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the last year Aurelia Metals grew its earnings per share, moving from a loss to a profit. When a company is just on the edge of profitability it can be well worth considering other metrics in order to more precisely gauge growth (and therefore understand share price movements). Revenue was pretty stable on last year, so deeper research might be needed to explain the share price rise. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. So we recommend checking out this free report showing consensus forecasts It's good to see that Aurelia Metals has rewarded shareholders with a total shareholder return of 70% in the last twelve months. Since the one-year TSR is better than the five-year TSR (the latter coming in at 2% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. Investors who like to make money usually check up on insider purchases, such as the price paid, and total amount bought. You can find out about the insider purchases of Aurelia Metals by clicking this link. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
3 ASX Growth Companies With Up To 23% Insider Ownership
As the Australian market navigates a period of slower trade and investor caution amid ongoing global tensions, identifying growth companies with significant insider ownership can offer valuable insights into potential investment opportunities. In this environment, where confidence is tempered by geopolitical uncertainties, stocks with strong insider commitment may signal a higher level of trust in the company's long-term prospects. Name Insider Ownership Earnings Growth Alfabs Australia (ASX:AAL) 10.8% 41.3% Fenix Resources (ASX:FEX) 21.1% 47.8% Cyclopharm (ASX:CYC) 11.3% 97.8% Acrux (ASX:ACR) 15.5% 106.9% Newfield Resources (ASX:NWF) 31.5% 72.1% Echo IQ (ASX:EIQ) 19.8% 111.1% Titomic (ASX:TTT) 11.2% 77.2% Plenti Group (ASX:PLT) 12.7% 85% Image Resources (ASX:IMA) 16.1% 127.3% BETR Entertainment (ASX:BBT) 38.6% 77.5% Click here to see the full list of 93 stocks from our Fast Growing ASX Companies With High Insider Ownership screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Aurelia Metals Limited is an Australian company involved in the exploration and production of mineral properties, with a market capitalization of A$456.99 million. Operations: The company's revenue is primarily derived from its operations at the Peak Mine (A$245.13 million), Dargues Mine (A$73.90 million), and Hera Mine (A$5.98 million). Insider Ownership: 23.9% Aurelia Metals shows promise as a growth company with substantial insider ownership, evidenced by significant insider buying in recent months. The company has returned to profitability, reporting A$17.95 million net income for the half-year ending December 2024 compared to a loss previously. While gold and silver production declined, copper output increased significantly. Analysts forecast robust annual earnings growth of 23.6%, outpacing the broader Australian market's expected growth rate of 11.7%. Unlock comprehensive insights into our analysis of Aurelia Metals stock in this growth report. The valuation report we've compiled suggests that Aurelia Metals' current price could be quite moderate. Simply Wall St Growth Rating: ★★★★★☆ Overview: Clarity Pharmaceuticals Ltd is a clinical stage radiopharmaceutical company focused on research and development of radiopharmaceutical products in Australia and the United States, with a market cap of A$539.87 million. Operations: The company's revenue segment consists of Radiopharmaceutical Development, generating A$10.78 million. Insider Ownership: 17.8% Clarity Pharmaceuticals demonstrates strong growth potential, driven by its innovative Cu-SAR-bisPSMA platform for prostate cancer treatment. Recent trial advancements show promising efficacy and safety, with significant PSA reductions in heavily pre-treated participants. The FDA's Fast Track Designation supports accelerated development. Despite a net loss of A$23.58 million for the half-year ending December 2024, revenue grew to A$10.94 million from A$6.52 million year-over-year, with forecasts indicating rapid revenue growth exceeding market averages. Take a closer look at Clarity Pharmaceuticals' potential here in our earnings growth report. Our valuation report here indicates Clarity Pharmaceuticals may be overvalued. Simply Wall St Growth Rating: ★★★★★★ Overview: IperionX Limited is involved in the exploration and development of mineral properties in the United States, with a market capitalization of approximately A$900.03 million. Operations: IperionX Limited's revenue segments are not specified in the provided text. Insider Ownership: 19.2% IperionX is poised for significant growth, driven by its Titan Critical Minerals Project in Tennessee and strategic U.S. partnerships, including a USD 47.1 million government award to enhance the titanium supply chain. Despite recent shareholder dilution and a net loss of USD 16.24 million for the half-year ending December 2024, IperionX's revenue is forecast to grow rapidly, outpacing market averages with expected profitability within three years, supported by innovative technologies and substantial insider ownership. Click here to discover the nuances of IperionX with our detailed analytical future growth report. Our comprehensive valuation report raises the possibility that IperionX is priced higher than what may be justified by its financials. Click through to start exploring the rest of the 90 Fast Growing ASX Companies With High Insider Ownership now. Contemplating Other Strategies? This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include ASX:AMI ASX:CU6 and ASX:IPX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
3 ASX Growth Companies With Up To 23% Insider Ownership
As the Australian market navigates a period of slower trade and investor caution amid ongoing global tensions, identifying growth companies with significant insider ownership can offer valuable insights into potential investment opportunities. In this environment, where confidence is tempered by geopolitical uncertainties, stocks with strong insider commitment may signal a higher level of trust in the company's long-term prospects. Name Insider Ownership Earnings Growth Alfabs Australia (ASX:AAL) 10.8% 41.3% Fenix Resources (ASX:FEX) 21.1% 47.8% Cyclopharm (ASX:CYC) 11.3% 97.8% Acrux (ASX:ACR) 15.5% 106.9% Newfield Resources (ASX:NWF) 31.5% 72.1% Echo IQ (ASX:EIQ) 19.8% 111.1% Titomic (ASX:TTT) 11.2% 77.2% Plenti Group (ASX:PLT) 12.7% 85% Image Resources (ASX:IMA) 16.1% 127.3% BETR Entertainment (ASX:BBT) 38.6% 77.5% Click here to see the full list of 93 stocks from our Fast Growing ASX Companies With High Insider Ownership screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Aurelia Metals Limited is an Australian company involved in the exploration and production of mineral properties, with a market capitalization of A$456.99 million. Operations: The company's revenue is primarily derived from its operations at the Peak Mine (A$245.13 million), Dargues Mine (A$73.90 million), and Hera Mine (A$5.98 million). Insider Ownership: 23.9% Aurelia Metals shows promise as a growth company with substantial insider ownership, evidenced by significant insider buying in recent months. The company has returned to profitability, reporting A$17.95 million net income for the half-year ending December 2024 compared to a loss previously. While gold and silver production declined, copper output increased significantly. Analysts forecast robust annual earnings growth of 23.6%, outpacing the broader Australian market's expected growth rate of 11.7%. Unlock comprehensive insights into our analysis of Aurelia Metals stock in this growth report. The valuation report we've compiled suggests that Aurelia Metals' current price could be quite moderate. Simply Wall St Growth Rating: ★★★★★☆ Overview: Clarity Pharmaceuticals Ltd is a clinical stage radiopharmaceutical company focused on research and development of radiopharmaceutical products in Australia and the United States, with a market cap of A$539.87 million. Operations: The company's revenue segment consists of Radiopharmaceutical Development, generating A$10.78 million. Insider Ownership: 17.8% Clarity Pharmaceuticals demonstrates strong growth potential, driven by its innovative Cu-SAR-bisPSMA platform for prostate cancer treatment. Recent trial advancements show promising efficacy and safety, with significant PSA reductions in heavily pre-treated participants. The FDA's Fast Track Designation supports accelerated development. Despite a net loss of A$23.58 million for the half-year ending December 2024, revenue grew to A$10.94 million from A$6.52 million year-over-year, with forecasts indicating rapid revenue growth exceeding market averages. Take a closer look at Clarity Pharmaceuticals' potential here in our earnings growth report. Our valuation report here indicates Clarity Pharmaceuticals may be overvalued. Simply Wall St Growth Rating: ★★★★★★ Overview: IperionX Limited is involved in the exploration and development of mineral properties in the United States, with a market capitalization of approximately A$900.03 million. Operations: IperionX Limited's revenue segments are not specified in the provided text. Insider Ownership: 19.2% IperionX is poised for significant growth, driven by its Titan Critical Minerals Project in Tennessee and strategic U.S. partnerships, including a USD 47.1 million government award to enhance the titanium supply chain. Despite recent shareholder dilution and a net loss of USD 16.24 million for the half-year ending December 2024, IperionX's revenue is forecast to grow rapidly, outpacing market averages with expected profitability within three years, supported by innovative technologies and substantial insider ownership. Click here to discover the nuances of IperionX with our detailed analytical future growth report. Our comprehensive valuation report raises the possibility that IperionX is priced higher than what may be justified by its financials. Click through to start exploring the rest of the 90 Fast Growing ASX Companies With High Insider Ownership now. Contemplating Other Strategies? This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include ASX:AMI ASX:CU6 and ASX:IPX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
15-04-2025
- Business
- Yahoo
3 Undiscovered Gems in Australia with Promising Potential
The Australian market has been experiencing a relatively stable period, with the ASX200 closing at 7,760 points and sectors such as Health Care showing positive momentum. In this environment of steady market activity and sector-specific movements, identifying stocks with unique growth potential can be particularly rewarding. Discovering these hidden gems requires looking beyond current volatility and focusing on companies that demonstrate resilience and innovation in their respective fields. Name Debt To Equity Revenue Growth Earnings Growth Health Rating Sugar Terminals NA 3.78% 4.30% ★★★★★★ Schaffer 25.47% 6.03% -5.20% ★★★★★★ Fiducian Group NA 9.97% 7.85% ★★★★★★ Hearts and Minds Investments NA 47.09% 49.82% ★★★★★★ Tribune Resources NA -10.33% -48.18% ★★★★★★ Djerriwarrh Investments 1.14% 8.17% 7.54% ★★★★★★ Red Hill Minerals NA 95.16% 40.06% ★★★★★★ Lycopodium 6.89% 16.56% 32.73% ★★★★★☆ Carlton Investments 0.02% 4.45% 3.97% ★★★★★☆ K&S 20.24% 1.58% 25.54% ★★★★☆☆ Click here to see the full list of 50 stocks from our ASX Undiscovered Gems With Strong Fundamentals screener. Let's explore several standout options from the results in the screener. Simply Wall St Value Rating: ★★★★☆☆ Overview: Aurelia Metals Limited is an Australian company focused on the exploration and production of mineral properties, with a market capitalization of A$406.22 million. Operations: Aurelia Metals generates revenue primarily from its Peak Mine, contributing A$245.13 million, followed by the Dargues Mine at A$73.90 million and Hera Mine at A$5.98 million. Aurelia Metals, a promising player in the mining sector, has shown significant improvements recently. The company reported a net income of A$17.95 million for the half-year ending December 2024, bouncing back from a loss of A$2.03 million the previous year. Sales increased to A$162.42 million from A$147.29 million, indicating robust operational performance despite lower gold and silver production compared to last year. Trading at 85% below its estimated fair value suggests potential upside for investors seeking undervalued opportunities. However, its interest coverage ratio of 2.6x indicates room for improvement in managing debt-related expenses efficiently. Take a closer look at Aurelia Metals' potential here in our health report. Understand Aurelia Metals' track record by examining our Past report. Simply Wall St Value Rating: ★★★★★☆ Overview: Tasmea Limited offers shutdown, maintenance, emergency breakdown, and capital upgrade services in Australia with a market capitalization of A$612.06 million. Operations: With a market capitalization of A$612.06 million, Tasmea Limited generates revenue primarily from providing shutdown, maintenance, emergency breakdown, and capital upgrade services in Australia. Tasmea's recent addition to the S&P/ASX All Ordinaries Index highlights its growing prominence. The company reported impressive half-year sales of A$246.65 million, up from A$193.32 million, with net income jumping to A$27.81 million from A$15.78 million a year earlier, showcasing solid growth momentum. Earnings per share rose to A$0.12 from A$0.08, reflecting improved profitability despite a high net debt to equity ratio of 49.7%. With earnings growth outpacing the construction industry at 75% and well-covered interest payments by EBIT (10x), Tasmea seems poised for continued expansion under fresh leadership and strategic focus on organic growth strategies. Get an in-depth perspective on Tasmea's performance by reading our health report here. Assess Tasmea's past performance with our detailed historical performance reports. Simply Wall St Value Rating: ★★★★★★ Overview: West African Resources Limited focuses on the mining, mineral processing, acquisition, exploration, and project development of gold projects in West Africa with a market capitalization of A$2.66 billion. Operations: West African Resources Limited generates its revenue primarily from mining operations, amounting to A$726.63 million. The company's financial structure includes a notable net profit margin trend, which can provide insights into its profitability. West African Resources is gearing up for a transformative phase with its Kiaka project, which is over 80% complete and set to start gold production in Q3 2025. This development could elevate annual output to about 420,000 ounces, enhancing revenue streams. The firm reported first-quarter gold production at 50,033 ounces and sales of 48,338 ounces at an average price of US$2,832 per ounce. With net income rising from A$146.87 million to A$223.84 million year-over-year and profit margins projected to grow from 30.7% to 35.3%, the company shows promising potential despite regulatory risks in Burkina Faso and market volatility concerns impacting future earnings projections between A$423.6 million and A$840 million by April 2028. West African Resources is set to boost gold output with its Kiaka project completion. Click here to explore the full narrative on the company's growth prospects. Click here to access our complete index of 50 ASX Undiscovered Gems With Strong Fundamentals. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:AMI ASX:TEA and ASX:WAF. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
